N. Vogelzang

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

Craig R. Nichols, Paul J. Catalano, Emily Crawford et al. · Journal of Clinical Oncology · 1998 · 347 citations

Medicine, Oncology, Cancer Drug Toxicity Management +10

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

Daniel J. George, Susan Halabi, Timothy F. Shepard et al. · PubMed · 2001 · 260 citations

Medicine, Cancer Biology, Oncology +14

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

George J. Bosl, Nancy L. Geller, Dean F. Bajorin et al. · Journal of Clinical Oncology · 1988 · 253 citations

Medicine, Oncology, Pharmacology +12

Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study.

Isabell A. Sesterhenn, R B Weiss, F. K. Mostofi et al. · Journal of Clinical Oncology · 1992 · 137 citations

Medicine, Oncology, Pathology +17

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

Dean F. Bajorin, A. Katz, Eliza Chan et al. · Journal of Clinical Oncology · 1988 · 125 citations

Medicine, Oncology, Cancer Control +13